{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-102988","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2024-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.910969+00:00","generated_at":"2026-05-31T01:40:11.242966+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Century Therapeutics appoints Morgan Conn, Ph.D. as CFO effective Oct 14, 2024","bullets":["Morgan Conn, formerly CBO of Pharvaris, appointed CFO; effective October 14, 2024.","Annual base salary of $470,000; target bonus of 40% of base; $100,000 signing bonus.","Equity award: option to purchase 360,890 shares and RSU covering 60,148 shares.","Option vests 25% on first anniversary, remainder monthly over 3 years; RSU vests 25% first year, quarterly thereafter.","Severance includes 9 months salary and COBRA, extended to 12 months upon change in control."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-102988","json":"https://secwatch.observer/filing/0001104659-24-102988.json","markdown":"https://secwatch.observer/filing/0001104659-24-102988.md","text":"https://secwatch.observer/filing/0001104659-24-102988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924102988/0001104659-24-102988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924102988/tm2424946d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:40:11.242966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25e87ecaad","claim":"Morgan Conn was appointed as Chief Financial Officer at Century Therapeutics, Inc..","evidence_excerpt":"On September 26, 2024, the Century Therapeutics, Inc. (the “Company”) announced the appointment of Morgan Conn, Ph.D. to serve as the Company’s Chief Financial Officer, effective October 14, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924102988/0001104659-24-102988-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}